CORAL ROSEBERRY: Open Payments
NPI 1255012860 · LA MESA, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,485 in 68 payments from 14 companies in 2025. Trend: 2023 $308 · 2024 $682 · 2025 $1,485
Food & beverage: $1,440Education: $45
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 4 | $306 |
| Amgen Inc. | 19 | $293 |
| Novo Nordisk Inc | 10 | $212 |
| Lilly USA, LLC | 10 | $169 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $139 |
| Otsuka America Pharmaceutical, Inc. | 5 | $118 |
| Lundbeck LLC | 2 | $45 |
| SHIELD THERAPEUTICS INC | 2 | $42 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $37 |
| ABBVIE INC. | 2 | $34 |
Products named: FARXIGA, REXULTI, EVENITY, JARDIANCE, OTEZLA, MOUNJARO, Wegovy, Ozempic.
Industry payments across CA — which companies pay providers there.
